Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 14/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16124433 | 0.93 | PCNA (0.80) | PCNAKDM4ELMNAPOLBTHRA | |
| SCHEMBL16124470 | 0.86 | PCNA (0.82) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL14485275 | 0.86 | PCNA (1.00) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL16124441 | 0.85 | PCNA (1.00) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL16124450 | 0.84 | PCNA (0.86) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL16126006 | 0.81 | PCNA (1.00) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL12642750 | 0.80 | PCNA (0.74) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL10610249 | 0.78 | PCNA (0.72) | PCNALMNAPOLBTHRATHRB | |
| SCHEMBL14485269 | 0.77 | PCNA (0.74) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL15500034 | 0.77 | PCNA (0.77) | PCNALMNAPOLBTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | MKI67, PCNA, PCLAF | PCNA 2/4885KDM4E 428/4885LMNA 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.